Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or...

To explore the efficacy and safety olverembatinib-based therapy in patients with transformed chronic myeloid leukemia in lymphoid blast phase (CML-LBP) or relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (R/R Ph+ ALL).

Data of patients with transformed CML-LBP or R/R Ph+ ALL receiving olverembatinib-based therapy from 24 academic centers in China were retrospectively interrogated. Cox regression model was utilized to identify covariates associated with survival.

75 patients with transformed CML-LBP (n = 26, 35%) and R/R Ph+ ALL (n = 49, 65%) were enrolled in this study. Median age was 51 years old (interquartile range [IQR], 40-57 years). With a median follow-up of 18 months (IQR, 11-27 months), excluding 1 patient with early death, 58 patients (78%) achieved complete remission/complete remission with incomplete hematologic recovery by 28 days. The 2-year probability of overall survival was 43% (95% Confidence Interval [CI], 29-56%) with median overall survival of 18 months (95% CI, 7-29 months). The therapy was well-tolerated. In multivariate analyses, higher hemoglobin concentration (Hazard ratio [HR] = 0.9 [0.7, 1.0], P = .049) and receiving a transplant (HR = 0.2 [0.1, 0.5], P = .001) were significantly-associated with better survival.

Olverembatinib-based therapy is effective and tolerable in patients with transformed CML-LBP and R/R Ph+ ALL.